+987.9%
MRNA vs INCY
+20.6%
+967.3%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | INCY | Excess | Alpha |
|---|---|---|---|---|
| 1D | +13.1% | +4.5% | +8.6% | +7.5% |
| 7D | +20.6% | +5.1% | +15.5% | +13.4% |
| 30D | +27.1% | +7.6% | +19.5% | +15.1% |
| 3M | +353.4% | +1.9% | +351.5% | +366.5% |
| 6M | +446.3% | +26.5% | +419.8% | +388.6% |
| YTD | +776.2% | +24.4% | +751.8% | +668.0% |
| 1Y | +987.9% | +19.4% | +968.6% | +878.7% |
| All | +987.9% | +20.6% | +967.3% | +878.7% |
Cumulative growth
Daily Returns
Daily percentage return beside INCY.
Daily Out/Under-Performance
Portfolio return minus INCY return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × INCY return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded INCY wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling